Mateon Therapeutics announces new interim preclinical data on CA4P
Mateon announced that CA4P in combination with a checkpoint inhibitor significantly reduced tumor size in a CT-26 colon cancer animal model. Mateon evaluated its lead investigational drug CA4P in a phase 2/3 clinical trial in platinum-resistant ovarian cancer, in a syngeneic mouse model. June 28, 2017